Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma

[1]  K. Lillemoe,et al.  Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. , 2020, Annals of Surgery.

[2]  M. Tempero,et al.  CA 19-9 Response , 2019, American journal of clinical oncology.

[3]  J. Cameron,et al.  Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  I. Ray-Coquard,et al.  Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study , 2019, Clinical Cancer Research.

[5]  M. Büchler,et al.  Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer , 2019, Annals of surgery.

[6]  M. Reni,et al.  A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. , 2018, European journal of cancer.

[7]  M. Reni,et al.  Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. , 2018, The lancet. Gastroenterology & hepatology.

[8]  J. Ayuso,et al.  Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial) , 2018, Cancer Chemotherapy and Pharmacology.

[9]  V. Torri,et al.  Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. , 2018, The lancet. Gastroenterology & hepatology.

[10]  M. Reni,et al.  Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. , 2017 .

[11]  A. Sa-cunha,et al.  Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. , 2016, Diagnostic and interventional imaging.

[12]  M. Reni,et al.  Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma , 2016, British Journal of Cancer.

[13]  M. Reni,et al.  CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Reni,et al.  (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial , 2015, Clinical Cancer Research.

[15]  H. Zeh,et al.  Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma , 2014, Annals of Surgical Oncology.

[16]  Laura H. Tang,et al.  A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma , 2014, Annals of surgery.

[17]  Jeffrey E. Lee,et al.  Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[18]  F. Motoi,et al.  Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial , 2013, Annals of Surgical Oncology.

[19]  Jeffrey E. Lee,et al.  Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators , 2012, Cancer.

[20]  Joshua A. Waters,et al.  Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? , 2011, Surgery.

[21]  M. Bloomston,et al.  Failure of Normalization of CA19-9 Following Resection for Pancreatic Cancer is Tantamount to Metastatic Disease , 2011, Annals of Surgical Oncology.

[22]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[23]  M. Schäfer,et al.  Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Reni,et al.  Dose-Intense PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) in Advanced Pancreatic Adenocarcinoma: A Dose-Finding Study , 2007, Cancer investigation.

[25]  M. Reni,et al.  Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma , 2006, Cancer Chemotherapy and Pharmacology.

[26]  M. Reni,et al.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. , 2005, The Lancet. Oncology.

[27]  Roberto J. Rivero-Soto,et al.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. , 2019, Annals of Surgery.

[28]  M. Reni,et al.  A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) , 2011, Cancer Chemotherapy and Pharmacology.